An interventional study of 3-nerve-targeted group and 5-nerve-targeted group in 3-Needle, 5-Needle and Genicular Nerve Block, sponsored by Tanta University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.
Sponsored by Tanta University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies in Pain by Tanta University — 10 open to participants now, 10 under way, 1 of them phase 3. Pain · Tanta University.
Among the 32 studies in Pain by Tanta University, this one is the 12th largest by planned enrollment, is one of 5 that started in 2026, is one of 30 with no phase, and was the 31st registered.
10,076 studies on the registry are indexed under Pain; 1,648 are open to participants now.
Browse Pain studies →10 of the 32 studies in Pain by Tanta University are open now, in 1 country. Recruiting first, the newest first:
Tanta University · Sites in Egypt
Ages 50+
Tanta University · Sites in Egypt
Ages 21–60
Tanta University · Sites in Egypt
Ages 21+
Tanta University · Sites in Egypt
Ages 5–7
Tanta University · Sites in Egypt
Ages 18+
By country, each count listing its studies:
Of the 930 Pain studies recruiting now, 384 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 220 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
First in 2020; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 80 is above the median of 66 across 8,512 interventional studies indexed under Pain.
Median enrollment 70 across the 32 interventional studies. Of the 21 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Tanta University is the lead sponsor of 1,015 studies on the registry; 321 are open to participants now.
Of its 15 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
3 of the studies in Pain by Tanta University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07789340Tanta UniversityUnipolar Versus Bipolar Radiofrequency Ablation in Knee Osteoarthritis Pain | 2027-06-01 |
| NCT07732556Tanta UniversityMidpoint Transverse Process to Pleura (MTP) Block vs Erector Spinae Plane (ESP) Block for Acute Herpes Zoster (HZ) Pain | 2027-06-01 |
| NCT07853170Tanta University3-Needle vs 5-Needle of Genicular Nerve Block on Pain and Quality of Life in Knee Osteoarthritis | 2027-09-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 32 studies in Pain by Tanta University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to compare the 3-needle and 5-needle of genicular nerve block on pain and quality of life in Knee osteoarthritis (KOA).
Knee osteoarthritis (KOA) is a common musculoskeletal disorder characterized by degeneration of articular cartilage and the subchondral bone. It leads to pain, stiffness, and functional decline in the affected knee joints.
Currently, the classical 3- nerve protocol targeting the superior medial, superior lateral, and inferior medial genicular nerves is the most commonly used technique for radiofrequency procedures.
Therefore, a five-needle Genicular nerve blocks (GNB) technique has been proposed to provide a more comprehensive blockade by targeting additional sensory branches.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients will receive 3-nerve protocol.
Other: 3-nerve-targeted group
Patients will receive 5-nerve protocol.
Other: 5-nerve-targeted group
Patients will receive 3-nerve protocol.
Patients will receive 5-nerve protocol.
Degree of pain
Each patient will be instructed about postoperative pain assessment with the numeric rating scale (NRS) score. NRS (0 represents "no pain" while 10 represents "the worst pain imaginable").
Time frame: 6 months postoperatively
Measurement of Quality of life
The Western Ontario and McMaster Universities Arthritis Index (WOMAC) is a self-administered health status questionnaire and consists of 24 items divided into 3 subscales: pain (5 items), stiffness (2 items), and physical function (17 items). Accordingly, higher scores on the WOMAC indicate worse pain, stiffness, and functional limitation. The WOMAC will be assessed at each follow-up point
Time frame: 6 months postoperatively
Patients' opioid medication use
Patients' opioid medication use will be evaluated before treatment and at 6 months after treatment.
Time frame: 6 months after treatment
Degree of patient satisfaction
Degree of patient satisfaction will be assessed on a 5-point Likert scale patient satisfaction (1, extremely dissatisfied; 2, unsatisfied; 3, neutral; 4, satisfied; 5, extremely satisfied)
Time frame: 6 months postoperatively
Plan to share: Yes — The data will be available upon a reasonable request from the corresponding author after the end of study for one year.
Supporting information: Study protocol
Time frame: After the end of study for one year.
Access criteria: The data will be available upon a reasonable request from the corresponding author.
Started Oct 2026 (actual). Primary completion is estimated for Sep 2027, 10 months after the start.
Of 3,749 non-industry interventional studies with no phase under Pain, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 23. This study's planned 10 months is close to that.
Counting every sponsor, half of 3,848 studies reached it within 10 months; a quarter within 4 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.